Pinho, Inês Soares deLuz, PauloAlves, LucyBrás, Raquel LopesPatel, VanessaMartins, Miguel EsperançaGonçalves, LisaFreitas, RitasSimão, DianaRoldán Galnares, MariaFernandes, IsabelCriado, Silvia ArtachoGamez Casado, SalvadorBaena Cañada, JoseVega, Isabel M. SaffieCosta, João G.Fernandes, Ana S.Sousa, Rita Teixeira deCosta, Luís2025-03-242025-03-242023-07-211173-2563http://hdl.handle.net/10400.1/26945Deescalation strategies omitting anthracyclines (AC) have been explored in early human epidermal growth factor receptor 2-positive breast cancer (HER2+ EBC), showing similar efcacy regarding pathological complete response (pCR) and long-term outcomes as AC-containing regimens. The standard treatment for this tumor subtype is based on chemotherapy and dual HER2 blockade with trastuzumab and pertuzumab, with AC-containing regimens remaining a frequent option for these patients, even in non-high-risk cases. The primary aim of this study was to assess and compare the efectiveness of neoadjuvant regimens with and without AC used in the treatment of HER2+ EBC in the clinical practice according to the pCR achieved with each.engEarly breast-cancerPertuzumab plus trastuzumabSafetyChemotherapyPaclitaxelEfficacyWomenRiskAnthracyclines versus no anthracyclines in the neoadjuvant strategy for HER2+ breast cancer: real-world evidencejournal article10.1007/s40261-023-01291-61179-1918